Young Youl Hyun

Metabolically Healthy Obesity and Development of Chronic Kidney Disease: A Cohort Study.

Context The risk for chronic kidney disease (CKD) among obese patients without metabolic abnormalities is unknown. Contribution In this cohort study of South Korean men and women, metabolically healthy overweight and obese participants had increased incidence of CKD compared with normal-weight participants. Caution Body mass index was a marker of obesity and was assessed only once at baseline. Implication Physicians should monitor metabolically healthy obese and overweight patients for CKD and counsel them about maintaining a healthy weight and lifestyle. Chronic kidney disease (CKD) is a major clinical and public health problem (1). It is a precursor for end-stage renal disease and a strong risk factor for cardiovascular morbidity and mortality (2). Its prevalence is increasing worldwide along with the growing prevalence of obesity and metabolic disease (3). Indeed, obesitymediated by hypertension, insulin resistance, hyperglycemia, dyslipidemia, and other metabolic abnormalitiesis a major risk factor for CKD (4). Although the role of obesity-induced metabolic abnormalities in CKD development is well-established, metabolically healthy obese (MHO) persons, seem to have a favorable profile with no metabolic abnormalities (5, 6). The association between MHO and CKD, however, is largely unknown. The only study available found no association (7), but the comparison between MHO and normal-weight participants could be biased because the reference group included overweight participants, and metabolically healthy participants were defined as those with fewer than 2 metabolic components. Therefore, we examined the association between categories of body mass index (BMI) and CKD in a large sample of metabolically healthy men and women who had health screening examinations. Methods Study Population The Kangbuk Samsung Health Study is a cohort study of South Korean men and women aged 18 years or older who had a comprehensive annual or biennial health examination at the clinics of the Kangbuk Samsung Hospital Health Screening Centers in Seoul and Suwon, South Korea (8). More than 80% of participants were employees of various companies and local governmental organizations and their spouses. In South Korea, the Industrial Safety and Health Act requires all employees to receive annual or biennial health screening examinations, offered free of charge. The remaining participants registered for the screening examinations on their own. Our analysis included all persons who had comprehensive health examinations from 1 January 2002 to 31 December 2009 and had at least 1 other screening examination before 31 December 2013 (that is, they all had a baseline visit and 1 follow-up visit [n=175859]) (Figure 1). We excluded persons who had metabolic abnormalities (5, 9, 10) or evidence of kidney disease at baseline (n=108263). We excluded those with fasting glucose levels of 100 mg/dL or greater or who used glucose-lowering agents; blood pressure (BP) of 130/85 mm Hg or greater or who used BP-lowering agents; triglyceride levels of 150 mg/dL or greater or who used lipid-lowering agents; high-density lipoprotein (HDL) cholesterol levels less than 40 mg/dL in men or less than 50 mg/dL in women; insulin resistance, defined as homeostasis model assessment of insulin resistance (HOMA-IR) scores of 2.5 or greater (11); estimated glomerular filtration rate (GFR) less than 60 mL/min/1.73 m2; proteinuria; history of CKD; or history of cancer. Among eligible participants (n=67596), we further excluded those with missing values in any of the study variables (n=5347 [7.9%]). The final sample size was 62249 participants (Figure 1), all of whom were metabolically healthy and did not have markers of kidney disease at baseline. This study was approved by the Institutional Review Board of the Kangbuk Samsung Hospital, which exempted the requirement for informed consent because we only accessed deidentified data routinely collected as part of health screening examinations. Figure 1. Study flow diagram. CKD = chronic kidney disease; HDL = high-density lipoprotein. * Participants in the screening program could have >1 criterion that made them ineligible for the study. Eligible participants could have missing data in >1 study variable. Measurements Data on medical history, medication use, family history, physical activity, alcohol intake, smoking habits, and education level were collected by a standardized, self-administered questionnaire. Anthropometry data, BP, and blood samples were obtained by trained staff during the examinations (8, 12). Smoking status was categorized as never, former, or current. Alcohol consumption was categorized as none, moderate (20 g per day), or high (>20 g per day). The weekly frequency of moderate- or vigorous-intensity physical activity was also assessed. Sitting BP, height, and weight were measured by trained nurses. Height was measured to the nearest 1 cm with a stadiometer while the participant stood barefoot. Weight was measured to the nearest 0.1 kg on a bioimpedance analyzer (InBody 3.0 and Inbody 720, Biospace), which was validated for reproducibility and accuracy of body composition measurements (13) and calibrated every morning before testing started. Body mass index was calculated as weight in kilograms divided by height in meters squared and was classified according to Asian-specific criteria (14) (underweight, BMI <18.5 kg/m2; normal weight, BMI of 18.5 to 22.9 kg/m2; overweight, BMI of 23 to 24.9 kg/m2; and obese, BMI 25 kg/m2). Blood specimens were sampled from the antecubital vein after at least a 10-hour fast. The methods for measuring serum levels of glucose, uric acid, total cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, HDL cholesterol, aspartate aminotransferase, alanine aminotransferase, -glutamyltransferase, insulin, and high-sensitivity C-reactive protein (hsCRP) have been reported elsewhere (8, 12). The Department of Laboratory Medicine of the Kangbuk Samsung Hospital has been accredited by the Korean Society for Laboratory Medicine and the Korean Association of Quality Assurance for Clinical Laboratories and participates in the College of American Pathologists Proficiency Testing survey. Insulin resistance was assessed with the HOMA-IR equation (fasting insulin [uU/mL]fasting glucose [mmol/L] 22.5). An ultrasonographic diagnosis of fatty liver was defined as a diffuse increase of fine echoes in the liver parenchyma compared with the kidney or spleen parenchyma (15, 16). During the study period, serum creatinine levels were measured with the kinetic alkaline picrate method (Jaffe method) in an automated chemistry analyzer (from 2002 to 2009, we used the Advia 1650a Autoanalyzer [Bayer Diagnostics]; from 2010 to 2013, we used the Modular D2400 [Roche]). The within-batch and total coefficients of variation were 1.8% to 3.9% for low-level and 1.4% to 1.8% for high-level quality control specimens throughout the study. Because the laboratory method that was used to measure serum creatinine levels from 2002 to 2009 was not traceable to isotope-dilution mass spectrometry, we estimated GFR by using the 4-variable Modification of Diet in Renal Disease Study equation (17). The conclusions did not change if we used the Chronic Kidney Disease Epidemiology Collaboration equation (18) for GFR estimation (data not shown). Urine protein was measured semiquantitatively by urine dipstick (URiSCAN Urine test strips, YD Diagnostics) tested on fresh, midstream urine samples and was reported in the following 6 grades: absent, trace, 1+, 2+, 3+, and 4+ (corresponding to protein levels of undetectable, 10 mg/dL, 30 mg/dL, 100 mg/dL, 300 mg/dL, and 1000 mg/dL, respectively). Proteinuria was defined as a grade of 1+ or greater. Statistical Analysis Person-years of follow-up were calculated from the date of the baseline health examination until the date of CKD diagnosis or the last screening examination, whichever came first. The cumulative incidence of CKD for baseline BMI categories (<18.5, 18.5 to 22.9, 23.0 to 24.9, or 25.0 kg/m2) were standardized to the empirical distribution of baseline confounders in the overall study sample with inverse probability weighting (19, 20). We first fitted a multinomial logistic regression to estimate each participants probability of being in his or her own BMI category given the observed confounders. Stabilized weights were then calculated as the inverse of the estimated conditional probabilities of exposure, further rescaled by the overall proportion of participants in each BMI category to reduce variability of weights across groups and to avoid influential observations involving extremely obese persons (19). For risk analyses, we fitted a spline-based, parametric survival model (21) according to the stabilized weights and stratified by BMI category to obtain smooth estimates of the CKD cumulative incidence curves that would have been seen in the entire population if every participant had been in each category (20). This survival model parameterized stratum-specific log cumulative hazards as distinct natural cubic splines of log time with 3 internal knots at the 25th, 50th, and 75th percentiles; allowed for interval-censored events (incident CKD occurred at an unknown time point between the visit at which CKD was diagnosed and the previous visit); and used robust SEs for spline parameters that accounted for the correlation induced by weighting (21). For comparison, we also applied weighted KaplanMeier methods to estimate nonparametric cumulative incidence curves for each BMI category. We used the previously mentioned weighted, spline-based survival model to calculate adjusted differences in cumulative incidences of CKD at 2, 5, and 10 years of follow-up of normal-weight participants compared with those in the other BMI categories. We calculated 95% CIs by applying delta methods to the robust variance estimates of spline parameters. In addition to risk differences, we

Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice.

Despite the emerging importance of fibroblast growth factor 21 (FGF21) as a metabolic hormone regulating energy balance, its direct effects on renal function remain unexplored. FGF21 was injected ip daily for 12 weeks into db/db mice. Compared with control vehicle injection, FGF21 treatment significantly improved lipid profiles and insulin resistance and resulted in significantly higher serum adiponectin levels. In contrast, serum insulin and 8-isoprostane levels were significantly decreased. Interestingly, FGF21 and its receptor components in the kidneys were found to be significantly up-regulated in db/db mice, which suggests an FGF21-resistant state. FGF21 treatment significantly down-regulated FGF21 receptor components and activated ERK phosphorylation. FGF21 administration also markedly decreased urinary albumin excretion and mesangial expansion and suppressed profibrotic molecule synthesis. Furthermore, FGF21 improved renal lipid metabolism and oxidative stress injury. In cultured renal cells, FGF21 was mainly expressed in mesangial cells, and knockdown of FGF21 expression by stealth small interfering RNA further aggravated high-glucose-induced profibrotic cytokine synthesis in mesangial cells. Our results suggest that FGF21 improves insulin resistance and protects against renal injury through both improvement of systemic metabolic alterations and antifibrotic effects in type 2 diabetic nephropathy. Targeting FGF21 could therefore provide a potential candidate approach for a therapeutic strategy in type 2 diabetic nephropathy.

Celastrol, an NF-κB Inhibitor, Improves Insulin Resistance and Attenuates Renal Injury in db/db Mice

The NF-κB pathway plays an important role in chronic inflammatory and autoimmune diseases. Recently, NF-κB has also been suggested as an important mechanism linking obesity, inflammation, and metabolic disorders. However, there is no current evidence regarding the mechanism of action of NF-κB inhibition in insulin resistance and diabetic nephropathy in type 2 diabetic animal models. We investigated the effects of the NF-κB inhibitor celastrol in db/db mice. The treatment with celastrol for 2 months significantly lowered fasting plasma glucose (FPG), HbA1C and homeostasis model assessment index (HOMA-IR) levels. Celastrol also exhibited significant decreases in body weight, kidney/body weight and adiposity. Celastrol reduced insulin resistance and lipid abnormalities and led to higher plasma adiponectin levels. Celastrol treatment also significantly mitigated lipid accumulation and oxidative stress in organs including the kidney, liver and adipose tissue. The treated group also exhibited significantly lower creatinine levels and urinary albumin excretion was markedly reduced. Celastrol treatment significantly lowered mesangial expansion and suppressed type IV collagen, PAI-1 and TGFβ1 expressions in renal tissues. Celastrol also improved abnormal lipid metabolism, oxidative stress and proinflammatory cytokine activity in the kidney. In cultured podocytes, celastrol treatment abolished saturated fatty acid-induced proinflammatory cytokine synthesis. Taken together, celastrol treatment not only improved insulin resistance, glycemic control and oxidative stress, but also improved renal functional and structural changes through both metabolic and anti-inflammatory effects in the kidney. These results suggest that targeted therapy for NF-κB may be a useful new therapeutic approach for the management of type II diabetes and diabetic nephropathy.

Environmental heavy metal exposure and chronic kidney disease in the general population.

Lead (Pb), mercury (Hg), and cadmium (Cd) are common heavy metal toxins and cause toxicological renal effects at high levels, but the relevance of low-level environmental exposures in the general population is controversial. A total of 1,797 adults who participated in the KNHANES (a cross-sectional nationally representative survey in Korea) were examined, and 128 of them (7.1%) had chronic kidney disease (CKD). Our study assessed the association between Pb, Hg, Cd exposure, and CKD. Blood Pb and Cd levels were correlated with CKD in univariate logistic regression model. However, these environmental heavy metals were not associated with CKD after adjustment for age, sex, BMI, smoking, hyperlipidemia, hypertension, diabetes, and these metals in multivariate logistic regression models. We stratified the analysis according to hypertension or diabetes. In the adults with hypertension or diabetes, CKD had a significant association with elevated blood Cd after adjustment, but no association was present with blood Pb and Hg. The corresponding odds ratio [OR] of Cd for CKD were 1.52 (95% confidence interval [CI], 1.05-2.19, P=0.026) in adults with hypertension and 1.92 (95% CI, 1.14-3.25, P=0.014) in adults with diabetes. Environmental low level of Pb, Hg, Cd exposure in the general population was not associated with CKD. However, Cd exposure was associated with CKD, especially in adults with hypertension or diabetes. This finding suggests that environmental low Cd exposure may be a contributor to the risk of CKD in adults with hypertension or diabetes. Graphical Abstract

Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction

Dipeptidyl peptidase IV (DPPIV) is an exopeptidase that modulates the function of several substrates, among which insulin-releasing incretin hormones are the most well known. DPPIV also modulate substrates involved in inflammation, cell migration, and cell differentiation. Although DPPIV is highly expressed in proximal renal tubular cells, the role of DPPIV inhibition in renal disease is not fully understood. For this reason, we investigated the effects of LC15-0444, a DPPIV inhibitor, on renal function in a mouse model of renal fibrosis. Eight-week-old C57/BL6 mice were subjected to unilateral ureteral obstruction (UUO) and were treated with LC15-0444 (a DPPIV inhibitor) at a dose of 150 mg/kg per day in food or vehicle for 14 days. DPPIV activity was significantly increased in obstructed kidneys, and reduced after treatment with LC15-0444. Administration of LC15-0444 resulted in a significant decrease in albuminuria, urinary excretion of 8-isoprostane, and renal fibrosis. DPPIV inhibition also substantially decreased the synthesis of several proinflammatory and profibrotic molecules, as well as the infiltration of macrophages. UUO significantly increased, and LC15-0444 markedly suppressed, levels of phosphorylated Smad2/3, TGFβ1, toll-like receptor 4, high-mobility group box-1, NADPH oxidase 4, and NF-κB. These results suggest that activation of DPPIV in the kidney has a role in the progression of renal disease and that targeted therapy inhibiting DPPIV may prove to be a useful new approach in the management of progressive renal disease, independent of mechanisms mediated by glucagon-like peptide-1.

Effects of Toll-like receptor antagonist 4,5-dihydro-3-phenyl-5-isoxasole acetic acid on the progression of kidney disease in mice on a high-fat diet.

Background Obesity-related metabolic disorders are closely associated with inflammation induced by innate immunity. Toll-like receptors (TLRs) play a pivotal role in the innate immune system by activating proinflammatory signaling pathways. GIT27 (4,5-dihydro-3-phenyl-5-isoxasole acetic acid) is an active immunomodulatory agent that primarily targets macrophages and inhibits secretion of tumor necrosis factor α [as well as interleukin (IL)-1β, IL-10, and interferon γ]. However, the effect of TLR antagonist on kidney diseases has rarely been reported. We investigated whether the TLR antagonist GIT27 has beneficial effects on the progression of kidney disease in obese mice on a high-fat diet (HFD). Methods Six-week-old male C57BL/6 mice were divided into three groups: mice fed with normal chow diet (N=4); mice fed with a HFD (60% of total calories from fat, 5.5% from soybean oil, and 54.5% from lard, N=4); and GIT27-treated mice fed with a HFD (N=7). Results Glucose intolerance, oxidative stress, and lipid abnormalities in HFD mice were improved by GIT27 treatment. In addition, GIT27 treatment decreased the urinary excretion of albumin and protein in obesity-related kidney disease, urinary oxidative stress markers, and inflammatory cytokine levels. This treatment inhibited the expression of proinflammatory cytokines in the kidneys and adipose tissue, and improved extracellular matrix expansion and tubulointerstitial fibrosis in obesity-related kidney disease. Conclusion TLR inhibition by administering GIT27 improved metabolic parameters. GIT27 ameliorates abnormalities of lipid metabolism and may have renoprotective effects on obesity-related kidney disease through its anti-inflammatory properties.

Sulodexide improves renal function through reduction of vascular endothelial growth factor in type 2 diabetic rats.

AIMS Sulodexide is a promising therapeutic drug for the management of diabetic nephropathy. Although sulodexide has demonstrated a renoprotective effect through its ability to restore glomerular ionic permselectivity, the exact mechanism is still not clear. We investigated the effects of long-term sulodexide treatment on diabetic nephropathy in Otsuka-Long-Evans-Tokushima-Fatty (OLETF) rats. MAIN METHODS Diabetic rats were treated with or without sulodexide at 10mg/kg/day in the drinking water for nine months. Renal morphology and changes in VEGF and p38 mitogen-activated protein kinase (p38 MAPK), urinary levels of albumin (UAE) and urinary VEGF excretion were determined. To define the direct effects of sulodexide, we performed an in vitro experiment using podocytes. KEY FINDINGS UAE was significantly higher in OLETF rats than in control LETO rats, and the sulodexide group showed significantly decreased UAE after six months of treatment. Interestingly, urinary VEGF levels were also significantly decreased in the sulodexide-treated group. In accordance with UAE and urinary VEGF changes, the renal expression of profibrotic molecules was significantly decreased after sulodexide treatment. In addition, the activation of p38 MAPK, assessed by measuring the level of phospho-specific p38 MAPK, increased in diabetic renal tissues and was markedly suppressed by sulodexide treatment. In cultured podocytes, sulodexide treatment significantly decreased high glucose-induced p38 MAPK activation and VEGF synthesis. SIGNIFICANCE Sulodexide directly suppresses VEGF synthesis through the p38 MAPK pathway in podocytes, and these results suggest that sulodexide may provide renoprotection via suppression of renal VEGF synthesis independently of glomerular basement membrane ionic permselectivity in type 2 diabetic rats.

Plasma concentration of soluble intercellular adhesion molecule-1 (sICAM-1) is elevated in type 2 diabetic patients, and sICAM-1 synthesis is associated with leptin-induced activation of the mitogen-activated protein kinase (MAPK) pathway.

The intercellular adhesion molecule-1 (ICAM-1) and leptin are important inflammatory biomarkers. We investigated whether plasma-soluble ICAM-1 levels were related to the diabetic nephropathy and systemic inflammation. One hundred forty-seven type 2 diabetic patients and 46 healthy control subjects were studied. Plasma sICAM-1 concentrations were significantly higher in the diabetic groups than controls and increased significantly as diabetic nephropathy advanced. Plasma sICAM-1 levels were positively correlated with body mass index, fasting and postprandial blood glucose, urinary albumin excretion, and negatively correlated with creatinine clearance. Multiple regression analysis showed that plasma leptin levels were associated with a significant increase in plasma sICAM-1 levels. In cultured HUVECs, leptin increased ICAM-1 production in a dose-dependent manner, and this stimulating effect of leptin on ICAM-1 expression was reversed by MEK inhibitor, PD98059. Overall, these findings suggest that activation of leptin synthesis in a diabetic environment promotes ICAM-1 activation via mitogen-activated protein kinase pathway in type 2 diabetic patients.

Nutritional Status in Adults with Predialysis Chronic Kidney Disease: KNOW-CKD Study

Adverse changes in nutrition are prevalent and are strong indicators of adverse outcomes in patients with chronic kidney disease (CKD). The International Society of Renal Nutrition and Metabolism (ISRNM) proposed a common nomenclature and diagnostic criteria to identify protein-energy wasting (PEW) in CKD patients. We examined the nutritional status in 1,834 adults with predialysis CKD enrolled in the KoreaN cohort study for Outcome in patients With Chronic Kidney Disease (KNOW-CKD) study. As there was a need for further understanding of nutritional status and associated factors in CKD, we evaluated the prevalence and associated factors of PEW in adults with predialysis CKD. The prevalence of PEW was about 9.0% according to ISRNM criteria and tended to increase with advanced stage in predialysis CKD. Those who concurrently had PEW, inflammation, and CVD were a small proportion (0.4%). In multivariate logistic regression model, PEW was independently associated with estimated glomerular filtration rate (eGFR) (odds ratio [OR], 0.98; 95% confidence interval [CI], 0.96–0.99), total CO2 (OR, 0.93; 95% CI, 0.87–0.99), physical activity (OR, 0.43; 95% CI, 0.26–0.69), comorbid diabetes (OR, 1.68; 95% CI, 1.09–2.59), and high sensitivity C-reactive protein (hs-CRP) (OR, 1.03; 95% CI, 1.01–1.06). Our study suggests that PEW increases with advanced CKD stage. PEW is independently associated with renal function, low total CO2, low physical activity, comorbid diabetes, and increased hs-CRP in adults with predialysis CKD.

The association between underweight and the development of albuminuria is different between sexes in relatively healthy Korean subjects

BACKGROUND There are limited data on the association between underweight and albuminuria. The aim of this study is to verify the effect of underweight on the development of albuminuria. METHODS Participants who underwent two health check-ups with a 2-year interval at a tertiary hospital in Korea between 2002 and 2009 were studied. After exclusion of participants with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m(2) or dipstick albuminuria ≥1+ at the first check-up, 53 876 participants were enrolled. We measured the incidence of albuminuria at the second check-up and calculated the odds ratio (OR) for the development of albuminuria according to body mass index (BMI). RESULTS After 2 years, 746 cases of incident albuminuria were observed among 53 876 participants. The effect of BMI on the development of albuminuria was modified by sex in a multivariate logistic model with adjustment for age, diabetes, hypertension, dyslipidaemia, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, uric acid, eGFR, current smoking status and alcohol intake (P-value for interaction <0.001). Compared with participants in the normal weight range (BMI, 18.5-22.9), the ORs for incident albuminuria were 1.93 [95% confidence interval (CI), 1.35-2.76; P ≤ 0.001], 1.19 (0.84-1.67; P = 0.329) and 0.71 (0.43-1.17; P = 0.177) in underweight (BMI, <18.5), overweight (BMI, 23.0-24.9) and obese (BMI, ≥25) women. However, the ORs were 0.9 (95% CI, 0.39-2.05; P = 0.794), 1.08 (0.84-1.38; P = 0.567) and 1.38 (1.09-1.75; P = 0.007) for each corresponding group of men. CONCLUSIONS Underweight was significantly associated with the development of albuminuria after 2 years in relatively healthy Korean females, but this relationship was not significant in males. This study suggests the need for more studies on the role of underweight in renal injury in men and women.